CEO Wayne Paterson explains in an interview with 180 Markets at the end of last year how our core technologies - ADAPT® anti-calcification tissue treatment & DurAVR™ 3D Single-piece aortic valve - have the potential to provide a functional cure for the treatment of Aortic Stenosis restoring the normal pre-disease hemodynamic status.